Pre-treatment neutrophil to lymphocyte ratio is a predictor of prognosis in endometrial cancer.
Inflammation and tumor immunology are important in the prognosis of various cancers. We herein investigated whether pre-treatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and serum cancer antigen 125 (CA125) predict recurrence and survival in patients with endometrial cancer (EC). We collected complete blood counts and clinicopathological data from medical records of 320 patients with EC; their pre-treatment NLR, PLR and CA125 were analyzed for correlations with recurrence and survival, retrospectively. Disease-free survival (DFS) and overall survival (OS) rates of patients with high NLR and CA125 were significantly shorter than those for patients with low NLR and CA125 (DFS: p=0.002 and p<0.001; OS: p<0.001 and p<0.001, respectively). Furthermore, NLR was also an independent predictive factor for mortality in multivariate analysis (hazard ratio (HR)=3.318; 95% confidence interval (CI)=1.154-9.538; p=0.026). Pre-treatment NLR is a predictor of poor prognosis in EC.